Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials
Circulation · 17.10.2023 · 148 (16) · 1207-1219
DOI: 10.1161/circulationaha.123.063946 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Circulation, erschienen am 17.10.2023. Verfasst von Behnood Bikdeli und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Medicine Division (B.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Non-ST Elevated Myocardial Infarction, Percutaneous Coronary Intervention, Myocardial Infarction, Thrombosis. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non–ST-segment–elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers. We sought to compare the outcomes of bivalirudin and heparin in patients with non–ST-segment–elevation myocardial infarction undergoing PCI. METHODS: We performed an individual patient data meta-analysis of patients with non–ST-segment–elevation myocardial infarction in all 5 trials that randomized ≥1000 patients with any myocardial infarction undergoing PCI to bivalirudin versus heparin (MATRIX [Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox], VALIDATE-SWEDEHEART [Bivalirudin Versus Heparin in ST-Segment and Non–ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies Registry Trial], ISAR-REACT 4 [Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4], ACUITY [Acute Catheterization and Urgent Intervention Triage Strategy], and BRIGHT [Bivalirudin in Acute Myocardial Infarction vs Heparin and GPI Plus Heparin Trial]). The primary effectiveness and safety end points were 30-day all-cause mortality and serious bleeding. RESULTS: A total of 12 155 patients were randomized: 6040 to bivalirudin (52.3% with a post-PCI bivalirudin infusion), and 6115 to heparin (53.2% with planned glycoprotein IIb/IIIa inhibitor use). Thirty-day mortality was not significantly different between bivalirudin and heparin (1.2% versus 1.1%; adjusted odds ratio, 1.24 [95% CI, 0.86–1.79]; P =0.25). Cardiac mortality, reinfarction, and stent thrombosis rates were also not significantly different. Bivalirudin reduced serious bleeding (both access site–related and non—access site–related) compared with heparin (3.3% versus 5.5%; adjusted odds ratio, 0.59; 95% CI, 0.48–0.72; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Medicine Division (B.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Thrombosis Research Group (B.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Yale-New Haven Hospital/Yale Center for Outcomes Research and Evaluation, New Haven, CT (B.B.).
- Lund University, Sweden (D.E.).
- Bern University Hospital, University of Bern, Switzerland (M.V., E.F.).
- Deutsches Herzzentrum München, Technische Universität, Munich, Germany (A.K., S.S.).
ORCID-Profile: Behnood Bikdeli, David Erlinge, Marco Valgimigli, Adnan Kastrati, Yaling Han, Philippe Gabriel Steg, Rod H Stables, Roxana Mehran, Stefan K James, Enrico Frigoli, Yi Li, Ghazaleh Mehdipoor, Shmuel Chen, Björn Redfors, Gregg W Stone
Zitieren
APA
Bikdeli, B., Erlinge, D., Valgimigli, M., Kastrati, A., Han, Y., Steg, P. G., Stables, R. H., Mehran, R., James, S. K., Frigoli, E., Goldstein, P., Li, Y., Shahzad, A., Schüpke, S., Mehdipoor, G., Chen, S., Redfors, B., Crowley, A., Zhou, Z., & Stone, G. W. (2023). Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. Circulation, 148(16), 1207-1219. https://doi.org/10.1161/circulationaha.123.063946
Vancouver
Bikdeli B, Erlinge D, Valgimigli M, Kastrati A, Han Y, Steg PG, et al. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. Circulation. 2023;148(16):1207-1219. doi:10.1161/circulationaha.123.063946
BibTeX
@article{Bikdeli2023,
author = {Bikdeli, Behnood and Erlinge, David and Valgimigli, Marco and Kastrati, Adnan and Han, Yaling and Steg, Philippe Gabriel and Stables, Rod H and Mehran, Roxana and James, Stefan K and Frigoli, Enrico and Goldstein, Patrick and Li, Yi and Shahzad, Adeel and Schüpke, Stefanie and Mehdipoor, Ghazaleh and Chen, Shmuel and Redfors, Björn and Crowley, Aaron and Zhou, Zhipeng and Stone, Gregg W},
title = {Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials},
journal = {Circulation},
year = {2023},
volume = {148},
number = {16},
pages = {1207--1219},
doi = {10.1161/circulationaha.123.063946}
}
EUVIMED